Despite the low in vitro cytotoxic activity that was predicted by the established association between platinum resistance and TP53 mutations in other tumors [63,64], carboplatin was included due to the long experience in the use of these agents in metastatic retinoblastoma treatment [20]. Here, TP53 is linked to retinoblastoma.